Richard A. Heyman
CIK: 0001584759
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (28 total)
- Oct 1, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Direct3.5K shares at avg. $12.91$45K - Oct 1, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Indirect3.2K shares at avg. $12.91$41K - Oct 1, 2026ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct3.5K shares at avg. $1.60$6K - Jul 24, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Indirect6.1K shares at avg. $12.02$73K - Jul 24, 2026ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct3.5K shares at avg. $1.60$6K - Jul 24, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Direct7K shares at avg. $12.02$84K - Jul 6, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Indirect300 shares at avg. $12.00$4K - Feb 17, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect1.2K shares at avg. $26.18$32K - Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
19.2K shares- - Jan 20, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect718 shares at avg. $26.96$19K - Jan 20, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect512 shares at avg. $26.46$14K - Jan 16, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Indirect3.2K shares at avg. $12.00$38K - Jan 16, 2026ORIC
Oric Pharmaceuticals, Inc.
Sale(S)Direct3.5K shares at avg. $12.00$42K - Jan 9, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect4.3K shares at avg. $25.00$107K - Jan 8, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect1.6K shares at avg. $25.00$41K - Jan 8, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect8K shares at avg. $25.04$201K - Jan 2, 2026ORIC
Oric Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
40K shares- - Oct 3, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct1.4K shares at avg. $3.75$5K - Oct 3, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct31.4K shares at avg. $1.60$50K - Jun 5, 2025PMVP
PMV Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
33.5K shares- - Feb 6, 2025ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
23K shares- - Jan 2, 2025ORIC
Oric Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Oct 18, 2024ELVN
Enliven Therapeutics, Inc.
Sale(S)Indirect753 shares at avg. $30.00$23K - Oct 18, 2024ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct817 shares at avg. $30.00$25K - Oct 15, 2024ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct1.3K shares at avg. $27.67$35K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 3,500 | $12.91 | $45,199 | Direct |
| Oct 1, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 3,200 | $12.91 | $41,325 | Indirect |
| Oct 1, 2026 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 3,500 | $1.60 | $5,600 | Direct |
| Jul 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 6,100 | $12.02 | $73,322 | Indirect |
| Jul 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 3,500 | $1.60 | $5,600 | Direct |
| Jul 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 7,000 | $12.02 | $84,140 | Direct |
| Jul 6, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 300 | $12.00 | $3,600 | Indirect |
| Feb 17, 2026 |  ELVN Enliven Therapeutics, Inc. | Sale(S) | 1,230 | $26.18 | $32,196 | Indirect |
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 19,234 | - | - | Direct |
| Jan 20, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 718 | $26.96 | $19,354 | Indirect |
| Jan 20, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 512 | $26.46 | $13,547 | Indirect |
| Jan 16, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 3,200 | $12.00 | $38,415 | Indirect |
| Jan 16, 2026 | ORIC Oric Pharmaceuticals, Inc. | Sale(S) | 3,500 | $12.00 | $42,016 | Direct |
| Jan 9, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 4,285 | $25.00 | $107,125 | Indirect |
| Jan 8, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 1,620 | $25.00 | $40,500 | Indirect |
| Jan 8, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 8,015 | $25.04 | $200,656 | Indirect |
| Jan 2, 2026 | ORIC Oric Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 40,000 | - | - | Direct |
| Oct 3, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 1,447 | $3.75 | $5,426 | Direct |
| Oct 3, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 31,353 | $1.60 | $50,165 | Direct |
| Jun 5, 2025 |  PMVP PMV Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 33,500 | - | - | Direct |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 23,014 | - | - | Direct |
| Jan 2, 2025 | ORIC Oric Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 753 | $30.00 | $22,592 | Indirect |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 817 | $30.00 | $24,512 | Direct |
| Oct 15, 2024 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 1,270 | $27.67 | $35,143 | Direct |
1-25 of 28 transactions
About Heyman Richard A.
Heyman Richard A. (SEC CIK 0001584759) files insider reports with the SEC as Director of Oric Pharmaceuticals, Inc. (ORIC), Director of Enliven Therapeutics, Inc. (ELVN) and Director of PMV Pharmaceuticals, Inc. (PMVP).
Signal8 holds 18 ownership filings by Heyman Richard A., all Form 4s, filed between Sep 18, 2024 and Oct 2, 2026. Those filings report 28 transactions, from Sep 16, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Heyman Richard A.'s filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Heyman Richard A.
- Oct 1, 2026: Open-market sales of ORIC shares (2 lines, Form 4, code S).
- Oct 1, 2026: Option exercise of ORIC shares (Form 4, code M).
- Jul 24, 2026: Open-market sale of ORIC shares (Form 4, code S).
- Jul 24, 2026: Option exercise of ORIC shares (Form 4, code M).
- Jul 24, 2026: Open-market sale of ORIC shares (Form 4, code S).
Other insiders filing for Oric Pharmaceuticals, Inc. (ORIC)
- Piscitelli Dominic, Chief Financial Officer
- You Angie, Director
- Kunkel Lori Anne, Director
- Hoerter Steven L., Director
- Dier Mardi, Director
- Multani Pratik S, Chief Medical Officer